Influenza Vaccination: A Summary for Clinicians
On This Page
- Who Should Get Vaccinated?
- What are the influenza vaccine options this season?
- Are any of the available flu vaccines recommended over others?
- When should vaccination occur?
- Vaccination for Children
- Vaccination for Adults
- People Who Should Not Be Vaccinated
- Vaccination of People with a History of Egg Allergy
- Egg Allergy
- Influenza Vaccines and Use of Influenza Antiviral Medications
- Concurrent Administration of Influenza Vaccine With Other Vaccines
All persons 6 months and older should be vaccinated annually.
Vaccination to prevent influenza is particularly important for persons who are at increased risk for severe complications from influenza as well as those people who live with or care for persons at higher risk for influenza-related complications, including health care personnel.
There are special considerations regarding vaccination of persons with history of egg allergy.
CDC recommends use of injectable influenza vaccines (including inactivated influenza vaccines and recombinant influenza vaccines) during 2017-2018. The nasal spray flu vaccine (live attenuated influenza vaccine or LAIV) should not be used during 2017-2018.
Both trivalent (three-component) and quadrivalent (four-component) flu vaccines will be available.
Trivalent flu vaccines include:
- Standard-dose trivalent shots (IIV3) that are manufactured using virus grown in eggs. Different flu shots are approved for different age groups. Most flu shots are given in the arm (muscle) with a needle. One trivalent vaccine formulation can be given with a jet injector, for persons aged 18 through 64 years.
- A high-dose trivalent shot, approved for people 65 and older.
- A recombinant trivalent shot that is egg-free, approved for people 18 years and older, including pregnant women.
- A trivalent flu shot made with adjuvant (an ingredient of a vaccine that helps create a stronger immune response in the patient’s body), approved for people 65 years of age and older (new this season).
Quadrivalent flu vaccines include:
- Quadrivalent flu shots approved for use in different age groups, including children as young as 6 months.
- An intradermal quadrivalent flu shot, which is injected into the skin instead of the muscle and uses a much smaller needle than the regular flu shot. It is approved for people 18 through 64 years of age.
- A quadrivalent flu shot containing virus grown in cell culture, which is approved for people 4 years of age and older.
- A recombinant quadrivalent flu shot approved for people 18 years of age and older, including pregnant women (new this season).
Package inserts should be consulted for recommended age groups and possible contraindications for each vaccine in addition to information regarding additional components of various vaccine formulations.
In addition, the Advisory Committee on Immunization Practices (ACIP), Influenza Vaccine Recommendations, 2016-17 should be consulted.
For the 2017-2018 flu season, the Advisory Committee on Immunization Practices (ACIP) recommends annual influenza vaccination for everyone 6 months and older with either the inactivated influenza vaccine (IIV) or the recombinant influenza vaccine (RIV). The nasal spray flu vaccine (live attenuated influenza vaccine or LAIV) should not be used during 2017-2018.There is no preference for one vaccine over another among the recommended, approved injectable influenza vaccines. There are many vaccine options to choose from, but the most important thing is for all people 6 months and older to get a flu vaccine every year. If you have questions about which vaccine is best for you, talk to your doctor or other health care professional.
Optimally, vaccination should occur before onset of influenza activity in the community. Health care providers should offer vaccination by the end of October, if possible. Vaccination should continue to be offered as long as influenza viruses are circulating. While seasonal influenza outbreaks can happen as early as October, most of the time influenza activity peaks between December and March, although activity can last as late as May. Since it takes about two weeks after vaccination for antibodies to develop in the body that protect against influenza virus infection, it is best that people get vaccinated so they are protected before influenza begins spreading in their community.
Children younger than 6 months old are the pediatric group at highest risk of serious influenza complications, but they are too young to get an influenza vaccine. The best way to protect young children is to make sure members of their household and their caregivers are vaccinated.
Influenza vaccination is recommended for all children 6 months of age and older.
Children 6 months through 8 years who have previously received 2 or more total doses of any influenza vaccine before July 1 only need one dose for 2016-17 season. The two previous doses do not need to have been given during the same season or consecutive seasons.
Children 6 months through 8 years who have previously received only 1 dose of influenza vaccine, or who have never received influenza vaccine previously, need two doses of vaccine to be fully protected for the 2016-17 season. The 2016-2017 ACIP recommendations has an algorithm to help guide clinician decision-making regarding vaccination of children 6 months through 8 years of age.
2 Dose Vaccination Instructions
The first dose should be given as soon as vaccine becomes available, and the second dose should be given at least 4 weeks after the first dose. The first dose “primes” the immune system; the second dose provides immune protection. Children who only get one dose but need two doses can have reduced or no protection from a single dose of flu vaccine. Two doses are necessary to protect these children. If your patient needs the two doses, begin the process early, so that children are protected before influenza starts circulating in your community. Make sure to remind the parent to follow up to get the child a second dose if they need one. It usually takes about two weeks after the second dose for protection to begin.
Children who require two doses of flu vaccine do not need to receive the same flu vaccine both times; live or inactivated vaccine can be used for either dose. (Within approved indications and recommendations, no preferential recommendation is made for any type or brand of licensed influenza vaccine over another.)
See Vaccine Dose Considerations for Children 6 Months through 8 Years of Age for more information.
Everyone 6 months of age and older are recommended to get the flu vaccine, including even the healthiest adults. Vaccination is especially important for people at high risk of serious influenza complications or people who live with or care for people at higher risk for serious complications.
Persons working in health care settings also should be vaccinated annually against influenza. Vaccination of health care professionals has been associated with reduced work absenteeism and with fewer deaths among nursing home patients.
People who have had a severe reaction to an influenza vaccination, and children younger than 6 months of age should not be vaccinated.
People who are moderately or severely ill with or without fever should usually wait until they recover before getting flu vaccine.
A history of Guillain-Barré Syndrome (GBS) within 6 weeks following receipt of influenza vaccine is a precaution for the use of influenza vaccine. Such individuals have a risk of recurrence of GBS with subsequent vaccination, and if not at high risk of severe influenza complications should generally not be vaccinated. However, while data are limited, the established benefits of influenza vaccination might outweigh the risks for many people who have a history of GBS and who also are at high risk for severe complications from influenza.
Most influenza vaccines are produced by growing influenza virus in embryonated chicken eggs, and therefore contain trace amounts of egg protein. See Persons with a History of Egg Allergy for complete information and an algorithm to guide decision-making for vaccination of persons with egg allergy.
All vaccines should be administered in settings in which personnel and equipment for rapid recognition and treatment of anaphylaxis are available.
A previous severe allergic reaction to influenza vaccine, regardless of the component suspected to be responsible for the reaction, is a contraindication to future receipt of the vaccine.
The recommendations for vaccination of people with egg allergies have not changed since last season (2016-2017).
People with egg allergies can receive any licensed, recommended age-appropriate influenza vaccine and no longer have to be monitored for 30 minutes after receiving the vaccine. People who have severe egg allergies should be vaccinated in a medical setting and be supervised by a health care provider who is able to recognize and manage severe allergic conditions.
- Administration of inactivated influenza vaccine to persons receiving influenza antiviral drugs for treatment or chemoprophylaxis is acceptable.
- Live-attenuated influenza vaccine should not be administered until 48 hours after cessation of influenza antiviral therapy.
- If influenza antiviral medications are administered within 2 weeks after receipt of live-attenuated influenza vaccine, the vaccine dose should be repeated 48 or more hours after the last dose of antiviral medication.
- Inactivated vaccines do not interfere with the immune response to other inactivated vaccines or to live vaccines.
- Inactivated or live vaccines can be administered simultaneously with live-attenuated influenza vaccine.
- However, after administration of a live vaccine, at least 4 weeks should pass before another live vaccine is administered.
- Prevention and Control of Seasonal Influenza with Vaccines, Recommendations of the Advisory Committee on Immunization Practices — United States, 2016–17 Influenza Season
- Seasonal Influenza Vaccination Resources for Health Professionals
- Flu Activity and Surveillance
For Your Patients
- Vaccine Information Statement: Inactivated Influenza Vaccine
- Vaccine Information Statement: Live, Intranasal Influenza Vaccine
VIS are information sheets produced by CDC that explain both the benefits and risks of a vaccine to vaccine recipients.
- Page last reviewed: September 7, 2016
- Page last updated: October 3, 2017
- Content source:
- Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases (NCIRD)
- Page maintained by: Office of the Associate Director for Communication, Digital Media Branch, Division of Public Affairs